Pirtobrutinib in Combination With Rituximab, Gemcitabine, Oxaliplatin With or Without Polatuzumab Vedotin in Covalent BTK Inhibitor-Pretreated Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Inclusion Criteria: * Histologically confirmed DLBCL (2016 WHO criteria) of MCD, BN2, N1 subtypes, double-expressor, intravascular large B-cell lymphoma, or other BTK-sensitive subtypes * Disease progression/relapse after covalent BTK inhibitor therapy * ≥1 measurable lesion (nodal \>15mm/extranodal \>10mm) on PET/CT within 28 days * Eastern Cooperative Oncology Group (ECOG) 0-2 * age ≥18 years * Adequate organ function: ANC ≥0.5×10⁹/L ；Platelets ≥50×10⁹/L (transfusion-independent)；Bilirubin ≤1.5×ULN; ALT/AST ≤2.5×ULN；Cr ≤1.5×ULN or CrCl ≥30mL/min；LVEF ≥50% (NYHA class \<III) * Life expectancy \>3 months * Sign the written ICF, and be able to comply with the visits and related procedures stipulated in the protocol; * Female subjects of childbearing potential or male subjects with female partners of childbearing potential must use effective contraception throughout the treatment period and for 90 days after the last treatment. Exclusion Criteria: * DLBCL with central nervous system (CNS) or meningeal involvement * Histologically transformed DLBCL * Contraindications or hypersensitivity to any drug in the combination regimen * Major surgery within 4 weeks prior to treatment (excluding vascular access placement or biopsy) * Any life-threatening illness, medical condition, or organ system dysfunction that, in the investigator's judgment, may compromise patient safety or compliance with study procedures * Poorly controlled cardiac clinical symptoms or diseases, including: …